preclinical data on RANK/RANKL inhibition in osteosarcoma and could serve as a hypothesis-generating approach for clinical trials in this patient population.
Introduction
Osteosarcoma is a rare primary malignant tumour of bone that can often be cured with multimodal approaches including combination chemotherapy and surgery [1] . Patients with primary osteosarcoma in the spine as well as male and older patients (aged >12 years) have an inferior prognosis [2, 3] . Treatment options are very limited in patients with inoperable locally advanced or metastatic disease that has progressed after chemotherapy or radiotherapy, and the outcome is poor [4] . A recently published phase II trial has suggested some benefit from treatment with the multi-target tyrosine kinase inhibitor sorafenib resulting in a clinical benefit rate of 29% (defined as improvement in the Pain Analgesic Score via the Brief Pain Inventory score) [5] . However, the benefit was short-lived, with a median progression-free survival of 4 months and a median overall survival of 7 months. The receptor activator of nuclear factor-ĸB (RANK) signalling pathway is activated by RANK ligand (RANKL) and is essential for bone homeostasis [6] . Osteoblasts secrete RANKL, which leads to the differentiation and activation of osteoclasts promoting the release of bone-derived growth factors and osteolysis [6] . RANK signalling has been associated in preclinical osteosarcoma models with increased cell mobility and anchorage-independent growth [7] . In vitro studies in osteosarcoma cell lines using either osteoprotegrin (a physiological antagonist of RANK) or RANK-Fc protein to inhibit RANK signalling resulted in a reduction in osteosarcoma cell migration, invasion ability and anchorage-independent viability [8, 9] . In mice models, a reduction in tumour incidence, local tumour growth and dissemination of lung metastases translating into prolonged survival of mice could be demonstrated by the same methods [10, 11] . Therefore, RANKL may represent a potential therapeutic target in osteosarcoma; however, so far, no clinical data using RANKL inhibition have been reported.
Case Presentation
A 37-year-old otherwise healthy man was initially diagnosed histologically with an osteoblastoma in the Th1 vertebra. Curettage was performed, but the lesion recurred within 6 months in Th1 and C7. A pathology review revealed the diagnosis of an osteoblastic, osteoblastoma-like osteosarcoma. The tumour was not 259 primarily resectable in toto, and, after interdisciplinary discussion, the patient was treated with induction chemotherapy (cisplatin, doxorubicin, high-dose methotrexate) in analogy to the EURA-MOS protocol [12] . After 3 cycles, local progression was noted, and the tumour remained unresectable, mainly because the patient was afraid of the potential surgical consequences. Instead, stereotactic radiotherapy (total dose: 80 Gy) was administered with little effect, and, after 2 months, further local progression was observed, and a new lesion at the resection margin of rib 1 was found. The patient received 3 cycles of second-line chemotherapy with ifosfamide, carboplatin and etoposide without any effect. At this point in time, treatment with sorafenib (400 mg twice daily) and denosumab (120 mg every 4 weeks) was initiated. The treatment has been well tolerated, with grade 2 hand-foot syndrome as the main side effect. A metabolic complete remission with intense calcifications at the areas of former 18 F-fluorodeoxyglucose uptake (C7, Th1, rib 1) was noted in a positron emission tomography CT 8 months after initiation of treatment, with ongoing response and lack of further metastases after currently 18 months of treatment ( fig. 1 ). Immunohistochemistry has been performed on formalinfixed tissue of the patient's primary tumour, demonstrating positivity for RANK in multinucleated giant cells and cytoplasmatic expression of RANKL in the mononuclear, osteoid-producing tumour cells ( fig. 2 ).
Discussion
RANK and RANKL have been shown to be overexpressed in osteosarcoma patients and appear to be related to inferior outcome [13, 14] . In a retrospective study on 91 patients, overexpression of RANK and RANKL by immunohistochemistry was found in 69 and 9%, respectively, and RANK was associated with inferior disease-free survival [13] . Another retrospective study included 40 patients, and positivity for RANK and RANKL was found in 50 and 75%, respectively, and RANKL was related to a poor response to chemotherapy and inferior overall survival [14] . Denosumab is a fully human monoclonal antibody against RANKL and effectively blocks the interaction between RANKL and RANK, leading to decreased bone resorption [15] . Denosumab is well tolerated and used in the treatment of osteoporosis as well as in patients with bone metastases from solid tumour, reducing the number of skeletal-related events [16] . It has also shown very encouraging activity in giant cell tumour of bone, a locally aggressive primary bone tumour in which RANKL plays a critical role in pathogenesis [17] , and this led to the approval of denosumab for the treatment of giant cell tumour by the European Medicines Agency. In vitro studies show that RANK activation initiates multiple signalling pathways beyond the usual target of nuclear factor-ĸB. Especially the ERK1/2 pathway has been found to be crucial for the promotion of anchorage-independent survival and invasion of osteoblastic cells [7] . This is even more interesting since it appears that a blockade of the ERK1/2 pathway might be one of the mechanisms of action of sorafenib in osteosarcoma [18, 19] . A synergistic effect of the combination of denosumab and sorafenib can therefore be proposed. No preclinical data have been published investigating this hypothesis.
To our knowledge, no reports on the treatment with denosumab or the combination of sorafenib and denosumab in the setting of osteosarcoma have been published so far. The exceptional response in our patient and the outlined preclinical evidence might serve as hypothesis generating and trigger an interest in prospective trials.
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